Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Schizophrenia

  Free Subscription


Articles published in Am J Psychiatry

Retrieve available abstracts of 95 articles:
HTML format
Text format



Single Articles


    April 2018
  1. TIIHONEN J, Tanskanen A, Taipale H
    20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
    Am J Psychiatry. 2018 Apr 6:appiajp201817091001.
    PubMed     Text format     Abstract available


  2. JEZEQUEL J, Lepleux M, Kahn RS, Honnorat J, et al
    Molecular Pathogenicity of Anti-NMDA Receptor Autoantibody From Patients With First-Episode Psychosis.
    Am J Psychiatry. 2018;175:382-383.
    PubMed     Text format    


  3. GHOSE S
    Substance-Induced Psychosis: An Indicator of Development of Primary Psychosis?
    Am J Psychiatry. 2018;175:303-304.
    PubMed     Text format    


    March 2018
  4. ANDERSON KK, Norman R, MacDougall A, Edwards J, et al
    Effectiveness of Early Psychosis Intervention: Comparison of Service Users and Nonusers in Population-Based Health Administrative Data.
    Am J Psychiatry. 2018 Mar 2:appiajp201717050480.
    PubMed     Text format     Abstract available


  5. KAUPPI K, Rosenthal SB, Lo MT, Sanyal N, et al
    Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia.
    Am J Psychiatry. 2018 Mar 2:appiajp201717040410.
    PubMed     Text format     Abstract available


  6. NOORDSY DL, Burgess JD, Hardy KV, Yudofsky LM, et al
    Therapeutic Potential of Physical Exercise in Early Psychosis.
    Am J Psychiatry. 2018;175:209-214.
    PubMed     Text format    


    February 2018
  7. PAYNE JL
    The Psychoses of Menstruation and Childbearingby Ian Brockington, M.D., F.R.C.P. Cambridge, England, Cambridge University Press, 2017, 391 pp., $140.00 (hardcover).
    Am J Psychiatry. 2018;175:190-191.
    PubMed     Text format    


  8. GOFF DC
    Optimizing the Pharmacologic Treatment of Individuals With First-Episode Psychosis.
    Am J Psychiatry. 2018;175:101-102.
    PubMed     Text format    


    December 2017
  9. MCGUIRE P, Robson P, Cubala WJ, Vasile D, et al
    Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
    Am J Psychiatry. 2017 Dec 15:appiajp201717030325.
    PubMed     Text format     Abstract available


  10. HAMILTON HK, Williams TJ, Ventura J, Jasperse LJ, et al
    Clinical and Cognitive Significance of Auditory Sensory Processing Deficits in Schizophrenia.
    Am J Psychiatry. 2017 Dec 5:appiajp201716111203.
    PubMed     Text format     Abstract available


    November 2017
  11. LIVNY A, Reichenberg A, Fruchter E, Yoffe R, et al
    A Population-Based Longitudinal Study of Symptoms and Signs Before the Onset of Psychosis.
    Am J Psychiatry. 2017 Nov 28:appiajp201716121384.
    PubMed     Text format     Abstract available


  12. STARZER MSK, Nordentoft M, Hjorthoj C
    Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis.
    Am J Psychiatry. 2017 Nov 28:appiajp201717020223.
    PubMed     Text format     Abstract available


  13. GOES FS, Sawa A
    Psychosis Beyond the 22q11.2 Deletion: Do Additional Genetic Factors Play a Role?
    Am J Psychiatry. 2017;174:1027-1029.
    PubMed     Text format    


  14. SCHOOLER NR
    Long-Term Outcomes of Psychosis: Naturalistic Follow-Up After Initial Hospitalization.
    Am J Psychiatry. 2017;174:1030-1031.
    PubMed     Text format    


  15. KOTOV R, Fochtmann L, Li K, Tanenberg-Karant M, et al
    Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project.
    Am J Psychiatry. 2017;174:1064-1074.
    PubMed     Text format     Abstract available


  16. VELTHORST E, Fett AJ, Reichenberg A, Perlman G, et al
    The 20-Year Longitudinal Trajectories of Social Functioning in Individuals With Psychotic Disorders.
    Am J Psychiatry. 2017;174:1075-1085.
    PubMed     Text format     Abstract available


    October 2017
  17. KANE JM
    Clozapine Reduces All-Cause Mortality.
    Am J Psychiatry. 2017;174:920-921.
    PubMed     Text format    


  18. RAHMAN T, Ash DM, Lauriello J, Rawlani R, et al
    Misleading Guidance From Pharmacogenomic Testing.
    Am J Psychiatry. 2017;174:922-924.
    PubMed     Text format    


    September 2017
  19. LEVITT JJ, Nestor PG, Levin L, Pelavin P, et al
    Reduced Structural Connectivity in Frontostriatal White Matter Tracts in the Associative Loop in Schizophrenia.
    Am J Psychiatry. 2017 Sep 15:appiajp201716091046.
    PubMed     Text format     Abstract available


    August 2017
  20. SANDOVAL LR, Torous J, Keshavan MS
    Smartphones for Smarter Care? Self-Management in Schizophrenia.
    Am J Psychiatry. 2017;174:725-728.
    PubMed     Text format    


    July 2017
  21. DAVIDSON M, Saoud J, Staner C, Noel N, et al
    Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Am J Psychiatry. 2017 Jul 28:appiajp201717010122.
    PubMed     Text format     Abstract available


  22. BASSETT AS, Lowther C, Merico D, Costain G, et al
    Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome.
    Am J Psychiatry. 2017 Jul 28:appiajp201716121417.
    PubMed     Text format     Abstract available


  23. WIMBERLEY T, MacCabe JH, Laursen TM, Sorensen HJ, et al
    Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia.
    Am J Psychiatry. 2017 Jul 28:appiajp201716091097.
    PubMed     Text format     Abstract available


  24. ANDREASSEN OA
    Diabetes and Schizophrenia-New Findings for an Old Puzzle.
    Am J Psychiatry. 2017;174:616-617.
    PubMed     Text format    


  25. PHILIP NS, Nelson BG, Frohlich F, Lim KO, et al
    Low-Intensity Transcranial Current Stimulation in Psychiatry.
    Am J Psychiatry. 2017;174:628-639.
    PubMed     Text format     Abstract available


  26. SHARMA A, Wolf DH, Ciric R, Kable JW, et al
    Common Dimensional Reward Deficits Across Mood and Psychotic Disorders: A Connectome-Wide Association Study.
    Am J Psychiatry. 2017;174:657-666.
    PubMed     Text format     Abstract available


    June 2017
  27. COYLE JT
    Cortical Pyramidal Neurons Show a Selective Loss of New Synapses in Chronic Schizophrenia.
    Am J Psychiatry. 2017;174:510-511.
    PubMed     Text format    


    May 2017
  28. LEUCHT S, Leucht C, Huhn M, Chaimani A, et al
    Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
    Am J Psychiatry. 2017 May 25:appiajp201716121358.
    PubMed     Text format     Abstract available


  29. GOFF DC, Falkai P, Fleischhacker WW, Girgis RR, et al
    The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia.
    Am J Psychiatry. 2017 May 5:appiajp201716091016.
    PubMed     Text format     Abstract available


  30. HORVITZ-LENNON M, Mattke S, Predmore Z, Howes OD, et al
    The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia.
    Am J Psychiatry. 2017;174:421-426.
    PubMed     Text format    


  31. NAKIMULI-MPUNGU E
    Our Most Troubling Madness: Case Studies in Schizophrenia Across Culturesedited by T.M. Luhrmann and Jocelyn Marrow. Oakland, University of California Press, 2016, 304 pp., $29.95 (paperback).
    Am J Psychiatry. 2017;174:490.
    PubMed     Text format    


  32. HAUSER RA, Factor SA, Marder SR, Knesevich MA, et al
    KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Am J Psychiatry. 2017;174:476-484.
    PubMed     Text format     Abstract available


  33. BOU KHALIL R
    On the Magical Thinking Related to Mental Health in Chad.
    Am J Psychiatry. 2017;174:427-428.
    PubMed     Text format    


    April 2017
  34. ROSENHECK RA, Estroff SE, Sint K, Lin H, et al
    Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis.
    Am J Psychiatry. 2017 Apr 21:appiajp201716111273.
    PubMed     Text format     Abstract available


  35. LAVRETSKY H
    Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.
    Am J Psychiatry. 2017;174:307-308.
    PubMed     Text format    


    March 2017
  36. MACDONALD ML, Alhassan J, Newman JT, Richard M, et al
    Selective Loss of Smaller Spines in Schizophrenia.
    Am J Psychiatry. 2017 Mar 31:appiajp201716070814.
    PubMed     Text format     Abstract available


  37. PATERSON C, Wang Y, Hyde TM, Weinberger DR, et al
    Temporal, Diagnostic, and Tissue-Specific Regulation of NRG3 Isoform Expression in Human Brain Development and Affective Disorders.
    Am J Psychiatry. 2017;174:256-265.
    PubMed     Text format     Abstract available


    February 2017
  38. NIEMELA S, Sourander A, Surcel HM, Hinkka-Yli-Salomaki S, et al
    Data Selection Importance in the Study of the Association Between Maternal Smoking During Pregnancy and Schizophrenia: Response to Meier et al.
    Am J Psychiatry. 2017;174:188.
    PubMed     Text format    


  39. ESSOCK SM
    When Social and Environmental Adversity Causes Schizophrenia.
    Am J Psychiatry. 2017;174:89-90.
    PubMed     Text format    


  40. MEIER SM, Mors O, Parner E
    Familial Confounding of the Association Between Maternal Smoking During Pregnancy and Schizophrenia.
    Am J Psychiatry. 2017;174:187.
    PubMed     Text format    


    January 2017
  41. RAJKUMAR AP, Horsdal HT, Wimberley T, Cohen D, et al
    Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study.
    Am J Psychiatry. 2017 Jan 20:appiajp201616040442.
    PubMed     Text format     Abstract available


    December 2016
  42. CROPLEY VL, Klauser P, Lenroot RK, Bruggemann J, et al
    Accelerated Gray and White Matter Deterioration With Age in Schizophrenia.
    Am J Psychiatry. 2016 Dec 6:appiajp201616050610.
    PubMed     Text format     Abstract available


  43. HOWES OD, McCutcheon R, Agid O, de Bartolomeis A, et al
    Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
    Am J Psychiatry. 2016 Dec 6:appiajp201616050503.
    PubMed     Text format     Abstract available


    November 2016
  44. BARRERA A
    Self Psychology and Psychosis: The Development of the Self During Intensive Psychotherapy of Schizophrenia and Other Psychosesby David Garfield and Ira Steinman. London, Karnac, 2015, 208 pp., $35.76 (paperback).
    Am J Psychiatry. 2016;173:1152-1153.
    PubMed     Text format    


    October 2016
  45. KIRKBRIDE JB, Hameed Y, Ankireddypalli G, Ioannidis K, et al
    The Epidemiology of First-Episode Psychosis in Early Intervention in Psychosis Services: Findings From the Social Epidemiology of Psychoses in East Anglia [SEPEA] Study.
    Am J Psychiatry. 2016 Oct 24:appiajp201616010103.
    PubMed     Text format     Abstract available


  46. KELLEHER I, Cannon M
    Putting Psychosis in Its Place.
    Am J Psychiatry. 2016;173:951-952.
    PubMed     Text format    


  47. CARPENTER WT
    Early Detection of Psychosis Vulnerability: Progress, Opportunity, and Caution.
    Am J Psychiatry. 2016;173:949-950.
    PubMed     Text format    


    September 2016
  48. BERGINK V, Rasgon N, Wisner KL
    Postpartum Psychosis: Madness, Mania, and Melancholia in Motherhood.
    Am J Psychiatry. 2016 Sep 9:appiajp201616040454.
    PubMed     Text format     Abstract available


  49. HAFIZI S, Tseng HH, Rao N, Selvanathan T, et al
    Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [18F]FEPPA.
    Am J Psychiatry. 2016 Sep 9:appiajp201616020171.
    PubMed     Text format     Abstract available


    August 2016
  50. DATTA D, Arion D, Roman KM, Volk DW, et al
    Altered Expression of ARP2/3 Complex Signaling Pathway Genes in Prefrontal Layer 3 Pyramidal Cells in Schizophrenia.
    Am J Psychiatry. 2016 Aug 13:appiajp201616020204.
    PubMed     Text format     Abstract available


  51. NEUHAUS AH
    Importance of Control Biotypes to Distinguish Distinct Psychosis Biotypes.
    Am J Psychiatry. 2016;173:838.
    PubMed     Text format    


  52. CLEMENTZ BA
    Challenges Facing the Identification of Neurobiologically Distinct Psychosis Subtypes: Response to Neuhaus.
    Am J Psychiatry. 2016;173:838-9.
    PubMed     Text format    


  53. LAURSEN TM, McGrath JJ
    The Strange Case of Smoking and Schizophrenia-The Epidemiology Detectives Are on the Trail.
    Am J Psychiatry. 2016;173:757-8.
    PubMed     Text format    


    July 2016
  54. CHUNG DW, Fish KN, Lewis DA
    Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia.
    Am J Psychiatry. 2016 Jul 22:appiajp201616010025.
    PubMed     Text format     Abstract available


  55. DE LA FUENTE-SANDOVAL C
    Potential Regional Differences in GABA Levels in Patients With Psychosis Compared With Control Subjects.
    Am J Psychiatry. 2016;173:734.
    PubMed     Text format    


  56. MARENCO S
    Response to de la Fuente-Sandoval: Challenges Measuring GABA Levels in Patients With Psychosis.
    Am J Psychiatry. 2016;173:734-5.
    PubMed     Text format    


  57. SARPAL DK, Lencz T, Malhotra AK
    In Support of Neuroimaging Biomarkers of Treatment Response in First-Episode Schizophrenia.
    Am J Psychiatry. 2016;173:732-3.
    PubMed     Text format    


  58. CARRION RE, Cornblatt BA, Burton CZ, Tso IF, et al
    Personalized Prediction of Psychosis: External Validation of the NAPLS-2 Psychosis Risk Calculator With the EDIPPP Project.
    Am J Psychiatry. 2016 Jul 1:appiajp201615121565.
    PubMed     Text format     Abstract available


  59. CANNON TD, Yu C, Addington J, Bearden CE, et al
    An Individualized Risk Calculator for Research in Prodromal Psychosis.
    Am J Psychiatry. 2016 Jul 1:appiajp201615070890.
    PubMed     Text format     Abstract available


    June 2016
  60. HELFER B, Samara MT, Huhn M, Klupp E, et al
    Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis.
    Am J Psychiatry. 2016 Jun 10:appiajp201615081035.
    PubMed     Text format     Abstract available


  61. ROBINSON DG
    Early Mortality Among People With Schizophrenia.
    Am J Psychiatry. 2016;173:554-5.
    PubMed     Text format    


    May 2016
  62. NIEMELA S, Sourander A, Surcel HM, Hinkka-Yli-Salomaki S, et al
    Prenatal Nicotine Exposure and Risk of Schizophrenia Among Offspring in a National Birth Cohort.
    Am J Psychiatry. 2016 May 24:appiajp201615060800.
    PubMed     Text format     Abstract available


  63. REUS VI, Fochtmann LJ, Eyler AE, Hilty DM, et al
    The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.
    Am J Psychiatry. 2016;173:543-6.
    PubMed     Text format    


  64. BLOOMFIELD PS, Howes OD, Turkheimer F, Selvaraj S, et al
    Response to Narendran and Frankle: The Interpretation of PET Microglial Imaging in Schizophrenia.
    Am J Psychiatry. 2016;173:537-8.
    PubMed     Text format    


  65. NARENDRAN R, Frankle WG
    Comment on Analyses and Conclusions of "Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study".
    Am J Psychiatry. 2016;173:536-7.
    PubMed     Text format    


  66. MALASPINA D
    Searching for the Seeds of Psychosis.
    Am J Psychiatry. 2016;173:450-1.
    PubMed     Text format    


  67. KEGELES LS
    Brain GABA Function and Psychosis.
    Am J Psychiatry. 2016;173:448-9.
    PubMed     Text format    


    April 2016
  68. MANRIQUE-GARCIA E, Ponce de Leon A, Dalman C, Andreasson S, et al
    Cannabis, Psychosis, and Mortality: A Cohort Study of 50,373 Swedish Men.
    Am J Psychiatry. 2016 Apr 22:appiajp201614050637.
    PubMed     Text format     Abstract available


  69. CADENHEAD KS, Mirzakhanian H
    A Case of Attenuated Psychosis Syndrome: A Broad Differential Diagnosis Requires Broad-Spectrum Treatment.
    Am J Psychiatry. 2016;173:321-9.
    PubMed     Text format    


  70. JAVITT DC
    Biotypes in Psychosis: Has the RDoC Era Arrived?
    Am J Psychiatry. 2016;173:313-4.
    PubMed     Text format    


    March 2016
  71. HAIG GM, Bain EE, Robieson WZ, Baker JD, et al
    A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective alpha7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
    Am J Psychiatry. 2016 Mar 4:appiajp201515010093.
    PubMed     Text format     Abstract available


    February 2016
  72. SCHNACK HG, van Haren NE, Nieuwenhuis M, Hulshoff Pol HE, et al
    Accelerated Brain Aging in Schizophrenia: A Longitudinal Pattern Recognition Study.
    Am J Psychiatry. 2016 Feb 26:appiajp201515070922.
    PubMed     Text format     Abstract available


  73. MARQUES TR, Natesan S, Niccolini F, Politis M, et al
    Phosphodiesterase 10A in Schizophrenia: A PET Study Using [C]IMA107.
    Am J Psychiatry. 2016 Feb 19:appiajp201515040518.
    PubMed     Text format     Abstract available


  74. MARDER SR
    Community Evidence of Clozapine's Effectiveness.
    Am J Psychiatry. 2016;173:103-4.
    PubMed     Text format    


    January 2016
  75. MARENCO S, Meyer C, Kuo S, van der Veen JW, et al
    Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings.
    Am J Psychiatry. 2016 Jan 22:appiajp201515020190.
    PubMed     Text format     Abstract available


  76. LAHTI AC
    Making Progress Toward Individualized Medicine in the Treatment of Psychosis.
    Am J Psychiatry. 2016;173:5-7.
    PubMed     Text format    


  77. CANNON TD
    Microglial Activation and the Onset of Psychosis.
    Am J Psychiatry. 2016;173:3-4.
    PubMed     Text format    


  78. SARPAL DK, Argyelan M, Robinson DG, Szeszko PR, et al
    Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.
    Am J Psychiatry. 2016;173:69-77.
    PubMed     Text format     Abstract available


    December 2015
  79. ALLEN P, Chaddock CA, Egerton A, Howes OD, et al
    Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis.
    Am J Psychiatry. 2015 Dec 18:appiajp201515040485.
    PubMed     Text format     Abstract available


  80. TIIHONEN J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, et al
    Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study.
    Am J Psychiatry. 2015 Dec 7:appiajp201515050618.
    PubMed     Text format     Abstract available


  81. CLEMENTZ BA, Sweeney JA, Hamm JP, Ivleva EI, et al
    Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers.
    Am J Psychiatry. 2015 Dec 7:appiajp201514091200.
    PubMed     Text format     Abstract available


  82. GONG Q, Lui S, Sweeney JA
    A Selective Review of Cerebral Abnormalities in Patients With First-Episode Schizophrenia Before and After Treatment.
    Am J Psychiatry. 2015 Dec 1:appiajp201515050641.
    PubMed     Text format     Abstract available


  83. THORNTON AE, Procyshyn RM, Barr AM, MacEwan GW, et al
    Cognition and Plasma Ratio of Clozapine to N-desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia.
    Am J Psychiatry. 2015;172:1259.
    PubMed     Text format    


  84. RAJJI TK
    Response to Thornton et al.
    Am J Psychiatry. 2015;172:1259-60.
    PubMed     Text format    


    November 2015
  85. ABI-DARGHAM A
    Imaging the "GABA Shift" in Schizophrenia.
    Am J Psychiatry. 2015;172:1062-1063.
    PubMed     Text format    


  86. CAIRNS MJ
    Circulating miRNA Biomarkers for Schizophrenia?
    Am J Psychiatry. 2015;172:1059-1061.
    PubMed     Text format    


  87. AKBARIAN S, Kundakovic M
    CHRNA7 and CHRFAM7A: Psychosis and Smoking? Blame the Neighbors!
    Am J Psychiatry. 2015;172:1054-1056.
    PubMed     Text format    


  88. HYDE TM, Bharadwaj RA
    Molecular Mechanisms and Timing of Cortical Immune Activation in Schizophrenia.
    Am J Psychiatry. 2015;172:1052-1053.
    PubMed     Text format    


  89. KUNII Y, Zhang W, Xu Q, Hyde TM, et al
    CHRNA7 and CHRFAM7A mRNAs: co-localized and their expression levels altered in the postmortem dorsolateral prefrontal cortex in major psychiatric disorders.
    Am J Psychiatry. 2015;172:1122-30.
    PubMed     Text format     Abstract available


    October 2015
  90. YUNG AR
    Toward Improved Risk Prediction in Individuals at High Risk of Psychotic Disorders.
    Am J Psychiatry. 2015;172:932-3.
    PubMed     Text format    


    September 2015
  91. KORNFELD DS
    Response to Review of Shrinks: The Untold Story of Psychiatry.
    Am J Psychiatry. 2015;172:910-1.
    PubMed     Text format    


  92. DUCHARME S, Price BH, Larvie M, Dougherty DD, et al
    Clinical Approach to the Differential Diagnosis Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders.
    Am J Psychiatry. 2015;172:827-37.
    PubMed     Text format    


  93. GOFF DC
    Brexpiprazole: A New Antipsychotic Following in the Footsteps of Aripiprazole.
    Am J Psychiatry. 2015;172:820-1.
    PubMed     Text format    


  94. WEIDEN PJ
    Helping Patients With Mental Illness Get Back to Work.
    Am J Psychiatry. 2015;172:817-9.
    PubMed     Text format    


  95. MCGURK SR, Mueser KT, Xie H, Welsh J, et al
    Cognitive Enhancement Treatment for People With Mental Illness Who Do Not Respond to Supported Employment: A Randomized Controlled Trial.
    Am J Psychiatry. 2015;172:852-61.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: